SG11201803732PA - Novel anti-angiogenic fusion polypeptides - Google Patents
Novel anti-angiogenic fusion polypeptidesInfo
- Publication number
- SG11201803732PA SG11201803732PA SG11201803732PA SG11201803732PA SG11201803732PA SG 11201803732P A SG11201803732P A SG 11201803732PA SG 11201803732P A SG11201803732P A SG 11201803732PA SG 11201803732P A SG11201803732P A SG 11201803732PA SG 11201803732P A SG11201803732P A SG 11201803732PA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion
- international
- polypeptides
- fusion polypeptides
- ang
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 230000004927 fusion Effects 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 10
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 230000001772 anti-angiogenic effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 102000019298 Lipocalin Human genes 0.000 abstract 1
- 108050006654 Lipocalin Proteins 0.000 abstract 1
- 241000255972 Pieris <butterfly> Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000007500 overflow downdraw method Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau res.. 00) (43) International Publication Date .... .....r el 8 June 2017 (08.06.2017) W I P0 1 PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/091850 Publication Number Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 19/00 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/22 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/AU2016/051168 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 30 November 2016 (30.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 15197019.1 30 November 2015 (30.11.2015) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PIERIS AUSTRALIA PTY LTD. [AU/AU]; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Level 8 Angel Place, 123 Pitt Street, Sydney, New South TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Wales 2000 (AU). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: OLWILL, Shane; Am Waldrand 23a, 85354 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Freising (DE). BEL MBA, Rachida Siham; Er- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, hardtstrasse 15, 80469 Munich (DE). WIEDENMANN, Alexander; Fuersteneckerstrasse 5, D-89077 Ulm (DE). GW, KM, ML, MR, NE, SN, TD, TG). Published: (74) Agent: FISHER ADAMS KELLY CALLINANS; Level 6, 175 Eagle Street, Brisbane, Queensland 4000 (AU). — with international search report (Art 21(3)) [Continued on next page] (54) Title: NOVEL ANTI-ANGIOGENIC FUSION POLYPEPTIDES (57) : The disclosure provides fusion polypeptides comprising a Figure 1 for Ang-2 for fusion moiety specific and another VEGF-A, which poly- be for antagonizing Ang-2 and VEGF-A. In a peptide can useful pre- ferred embodiment, the Ang-2-specific moiety is comprised of a human lipocalin Such fusion =\ (hNGAL) mutein. \ , % 'c neutrophil gelatinase associated , ,,, % polypeptide can be used in many phannaceutical applications, for ex- b\ ' ample, as an agent useful to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making the fusion polypeptides de- • ; 3 1 scribed herein as well as compositions comprising such fusion - poly V \" peptides. The present disclosure further relates to nucleic acid molecules encoding such fusion their amino acid sequences and to polypeptides, for fusion methods the generation of such polypeptides and nucleic acid molecules. In addition, the application discloses therapeutic and/or dia - SW O's: hand 11 SEQ ID ND's: 9 and 10 gnostic uses of such fusion polypeptide as well as compositions compris- ing one or more of such fusion polypeptides. \ • t ., \• kk4k kV Il ki . 4t in Ot C:: , Il Cr1 SEQ ID ND's: S 0 ---.... IN 11 0 ei $ and 15 SEQ ID NO's: 9 and 14 O WO 2017/091850 Al IMEDIMOMOI VIII IIIII VIII F 0 10 IIMMOEIMI00110MOVOIMIE — before the expiration of the time limit for amending the — with sequence listing part of description (Rule 5.2(a)) claims and amendments to be (Rule republished 48.2(h)) in the event of receipt of
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197019 | 2015-11-30 | ||
| PCT/AU2016/051168 WO2017091850A1 (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803732PA true SG11201803732PA (en) | 2018-06-28 |
Family
ID=54754521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803732PA SG11201803732PA (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
| SG10201911499TA SG10201911499TA (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911499TA SG10201911499TA (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10703810B2 (en) |
| EP (1) | EP3383921A4 (en) |
| JP (1) | JP2019505565A (en) |
| KR (1) | KR20180083943A (en) |
| CN (1) | CN108699162A (en) |
| AU (1) | AU2016363668A1 (en) |
| BR (1) | BR112018010887A2 (en) |
| CA (1) | CA3004918A1 (en) |
| EA (1) | EA035586B1 (en) |
| MX (1) | MX2018006559A (en) |
| SG (2) | SG11201803732PA (en) |
| WO (1) | WO2017091850A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CN112203679A (en) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | IL-6 antibodies and fusion constructs and conjugates thereof |
| CN109829882B (en) * | 2018-12-18 | 2020-10-27 | 广州比格威医疗科技有限公司 | Method for predicting diabetic retinopathy stage by stage |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20240182553A1 (en) * | 2021-03-25 | 2024-06-06 | Nanjing GenScript Biotech Co., Ltd. | Antibody fusion proteins and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE76311T1 (en) | 1986-08-19 | 1992-06-15 | Genentech Inc | DEVICE AND DISPERSION FOR INTRAPULMONARY DELIVERY OF POLYPEPTIDE GROWTH SUBSTANCES AND CYTOKINES. |
| JPH01215289A (en) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | Production of normal human serum albumin a through gene recombination |
| FR2649991B2 (en) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| ATE299892T1 (en) | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS |
| DE4417598A1 (en) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Use of the tetracycline promoter for the stringently regulated production of recombinant proteins in prokaryotic cells |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (en) | 1996-10-10 | 2011-09-29 | Iba Gmbh | streptavidin muteins |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| NZ508249A (en) | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (en) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteins of the bilin binding protein |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| JP2007284351A (en) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | Substances that suppress amyloid protein aggregation and their actions |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2006078717A2 (en) * | 2005-01-19 | 2006-07-27 | Beth Israel Deaconess Medical Center | Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis |
| CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| JP5746861B2 (en) | 2007-10-19 | 2015-07-08 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | Antibodies that bind to mammalian NGAL and uses thereof |
| US20110076723A1 (en) * | 2008-05-23 | 2011-03-31 | Samsung Electronics Co., Ltd. | Antibody-peptide fused synergibody |
| JP5711118B2 (en) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | HNGAL and affinity protein muteins with affinity for a given target |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| WO2010111625A1 (en) * | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| RU2564125C2 (en) | 2009-12-07 | 2015-09-27 | Пирис Аг | Muteins of human lipocalin 2 (lcn2, hngal) with affinity to certain target |
| TWI426920B (en) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody |
| DK2606061T3 (en) * | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | HEPCIDIN BINDING PROTEINS |
| AU2011331232B2 (en) | 2010-11-15 | 2015-05-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| PE20150361A1 (en) * | 2012-07-13 | 2015-03-14 | Roche Glycart Ag | ANTI-VEGF / ANTI-ANG-2 BISPECIFIC ANTIBODIES AND THEIR USE IN THE TREATMENT OF EYE VASCULAR DISEASES |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| JP2016528167A (en) * | 2013-04-29 | 2016-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Human FcRn binding modified antibody and method of use |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| RU2723034C2 (en) * | 2014-05-22 | 2020-06-08 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Novel specific binding polypeptides and routes of use thereof |
| AR103477A1 (en) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | VEGFA / ANG2 COMPOUNDS |
| WO2016120307A1 (en) | 2015-01-28 | 2016-08-04 | Pieris Ag | Novel proteins specific for angiogenesis |
| WO2016131804A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| DK3292137T3 (en) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | PROTEINS SPECIFIC FOR CD137 |
| BR112017020961A2 (en) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | mutein, nucleic acid molecule, host cell, mutein production method and binding method |
-
2016
- 2016-11-30 SG SG11201803732PA patent/SG11201803732PA/en unknown
- 2016-11-30 EA EA201891141A patent/EA035586B1/en not_active IP Right Cessation
- 2016-11-30 CN CN201680080597.2A patent/CN108699162A/en active Pending
- 2016-11-30 AU AU2016363668A patent/AU2016363668A1/en not_active Abandoned
- 2016-11-30 US US15/777,340 patent/US10703810B2/en not_active Expired - Fee Related
- 2016-11-30 MX MX2018006559A patent/MX2018006559A/en unknown
- 2016-11-30 CA CA3004918A patent/CA3004918A1/en not_active Abandoned
- 2016-11-30 BR BR112018010887A patent/BR112018010887A2/en not_active Application Discontinuation
- 2016-11-30 JP JP2018546726A patent/JP2019505565A/en active Pending
- 2016-11-30 KR KR1020187018593A patent/KR20180083943A/en not_active Withdrawn
- 2016-11-30 EP EP16869402.4A patent/EP3383921A4/en not_active Withdrawn
- 2016-11-30 WO PCT/AU2016/051168 patent/WO2017091850A1/en not_active Ceased
- 2016-11-30 SG SG10201911499TA patent/SG10201911499TA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3383921A1 (en) | 2018-10-10 |
| AU2016363668A1 (en) | 2018-05-24 |
| EA035586B1 (en) | 2020-07-10 |
| US20180334499A1 (en) | 2018-11-22 |
| EA201891141A1 (en) | 2018-10-31 |
| US10703810B2 (en) | 2020-07-07 |
| KR20180083943A (en) | 2018-07-23 |
| CA3004918A1 (en) | 2017-06-08 |
| WO2017091850A1 (en) | 2017-06-08 |
| CN108699162A (en) | 2018-10-23 |
| JP2019505565A (en) | 2019-02-28 |
| SG10201911499TA (en) | 2020-01-30 |
| EP3383921A4 (en) | 2019-04-17 |
| BR112018010887A2 (en) | 2018-11-21 |
| MX2018006559A (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803732PA (en) | Novel anti-angiogenic fusion polypeptides | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201905997SA (en) | Method for the production of alkane sulfonic acids | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201909957TA (en) | Engineered ligase variants | |
| SG11202000274RA (en) | Oligonucleotide compositions and methods thereof | |
| SG11201806639VA (en) | New streptococcal proteases | |
| SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201805191SA (en) | Yeast cell | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201900400QA (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201808964PA (en) | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201805497QA (en) | Mutated truncated von willebrand factor | |
| SG11201810040WA (en) | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |